drugset
drugset / Trial / NCT06048887

Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers

NCT06048887 ↗

Phase 1 Completed 88 enrolled Crinetics Pharmaceuticals Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Phase 1, first-in-human, double-blind, randomized, placebo-controlled study to evaluate the safety of CRN04894 in healthy volunteers as well as the relationship between exposure and pharmacodynamic (PD) parameters.

Timeline

Start
2020-12-18
Primary completion
2022-04-11
Completion
2022-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Atumelnant Small molecule — Oral

Indications

No indication recorded.